Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016 (2016), Article ID 4757405, 25 pages
http://dx.doi.org/10.1155/2016/4757405
Clinical Study

Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer

1Division of Gastrointestinal Surgery, Nottingham Digestive Diseases Centre, Faculty of Medicine and Health Sciences, University of Nottingham, E Floor, West Block, Queen’s Medical Centre, Derby Rd, Nottingham NG7 2UH, UK
2Research & Development Department, Lincoln Breast Unit, Lincoln County Hospital, Greetwell Road, Lincoln LN2 5QY, UK
3Department of Pathology, PathLinks, Lincoln County Hospital, Greetwell Road, Lincoln LN2 5QY, UK
4Academic Department of Pathology, Faculty of Medicine and Health Sciences, University of Nottingham, A Floor, West Block, Queens Medical Centre, Derby Road, Nottingham NG7 2UH, UK

Received 8 February 2016; Revised 19 August 2016; Accepted 24 August 2016

Academic Editor: Yi Zhang

Copyright © 2016 Viriya Kaewkangsadan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Aloysius, L. Walker, and O. Eremin, “Cancer and the immune response,” in Essential Immunology for Surgeons, O. Eremin and H. Sewell, Eds., chapter 4, pp. 237–302, OUP, Oxford, UK, 2011. View at Google Scholar
  2. W. H. Fridman, F. Pagès, C. Sautès-Fridman, and J. Galon, “The immune contexture in human tumours: impact on clinical outcome,” Nature Reviews Cancer, vol. 12, no. 4, pp. 298–306, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Galon, H. K. Angell, D. Bedognetti, and F. M. Marincola, “The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures,” Immunity, vol. 39, no. 1, pp. 11–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Angell and J. Galon, “From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer,” Current Opinion in Immunology, vol. 25, no. 2, pp. 261–267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. M. W. L. Teng, S. F. Ngiow, A. Ribas, and M. J. Smyth, “Classifying cancers based on T-cell infiltration and PD-L1,” Cancer Research, vol. 75, no. 11, pp. 2139–2145, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Zhang, J. R. Conejo-Garcia, D. Katsaros et al., “Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer,” New England Journal of Medicine, vol. 348, no. 3, pp. 203–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Pagès, A. Berger, M. Camus et al., “Effector memory T cells, early metastasis, and survival in colorectal cancer,” The New England Journal of Medicine, vol. 353, no. 25, pp. 2654–2666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Schiavoni, L. Gabriele, and F. Mattei, “The tumor microenvironment: a pitch for multiple players,” Frontiers in Oncology, vol. 3, article 90, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Denkert, S. Loibl, A. Noske et al., “Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 105–113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Andre, N. Berrada, and C. Desmedt, “Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients,” Current Opinion in Oncology, vol. 22, no. 6, pp. 547–551, 2010. View at Publisher · View at Google Scholar
  11. R. Yamaguchi, M. Tanaka, A. Yano et al., “Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer,” Human Pathology, vol. 43, no. 10, pp. 1688–1694, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. A. Oldford, J. D. Robb, D. Codner, V. Gadag, P. H. Watson, and S. Drover, “Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients,” International Immunology, vol. 18, no. 11, pp. 1591–1602, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Ladoire, L. Arnould, L. Apetoh et al., “Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3+ regulatory T cells,” Clinical Cancer Research, vol. 14, no. 8, pp. 2413–2420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Balsari, A. Merlo, P. Casalini et al., “FOXP3 expression and overall survival in breast cancer,” Journal of Clinical Oncology, vol. 27, no. 11, pp. 1746–1752, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. M. A. Mahmoud, E. C. Paish, D. G. Powe et al., “Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer,” Journal of Clinical Oncology, vol. 29, no. 15, pp. 1949–1955, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. M. A. Mahmoud, E. C. Paish, D. G. Powe et al., “An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer,” Breast Cancer Research and Treatment, vol. 127, no. 1, pp. 99–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Zitvogel, L. Apetoh, F. Ghiringhelli, and G. Kroemer, “Immunological aspects of cancer chemotherapy,” Nature Reviews Immunology, vol. 8, no. 1, pp. 59–73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Aloysius, C. Verma, and O. Eremin, “Therapy and host defences,” in Essential Immunology for Surgeons, O. Eremin and H. Sewell, Eds., chapter 7, pp. 379–402, OUP, Oxford, UK, 2011. View at Google Scholar
  19. G. Kroemer, L. Galluzzi, O. Kepp, and L. Zitvogel, “Immunogenic cell death in cancer therapy,” Annual Review of Immunology, vol. 31, pp. 51–72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Verma, V. Kaewkangsadan, J. M. Eremin et al., “Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery,” Journal of Translational Medicine, vol. 13, article 180, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Verma, J. M. Eremin, A. Robins et al., “Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC,” Journal of Translational Medicine, vol. 11, no. 1, article 16, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. A. M. Malyguine, S. L. Strobl, and M. R. Shurin, “Immunological monitoring of the tumor immunoenvironment for clinical trials,” Cancer Immunology, Immunotherapy, vol. 61, no. 2, pp. 239–247, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. G. von Minckwitz, M. Untch, J.-U. Blohmer et al., “Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes,” Journal of Clinical Oncology, vol. 30, no. 15, pp. 1796–1804, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Eremin, G. Cowley, L. G. Walker, E. Murray, M. Stovickova, and O. Eremin, “Women with large (3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival,” SpringerPlus, vol. 4, article 9, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. K. N. Ogston, I. D. Miller, S. Payne et al., “A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival,” Breast, vol. 12, no. 5, pp. 320–327, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. L. G. Walker, J. M. Eremin, M. M. Aloysius et al., “Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer,” BMC Cancer, vol. 11, article 179, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Oda, K. Shimazu, Y. Naoi et al., “Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients,” Breast Cancer Research and Treatment, vol. 136, no. 1, pp. 107–116, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Demir, S. Yigit, H. Ellidokuz et al., “Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs,” Clinical & Experimental Metastasis, vol. 30, no. 8, pp. 1047–1062, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. M. V. Dieci, C. Criscitiello, A. Goubar et al., “Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study,” Annals of Oncology, vol. 25, no. 3, pp. 611–618, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Salgado, C. Denkert, S. Demaria et al., “The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: recommendations by an International TILS Working Group 2014,” Annals of Oncology, vol. 26, no. 2, Article ID mdu450, pp. 259–271, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Leffers, M. J. M. Gooden, R. A. De Jong et al., “Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer,” Cancer Immunology, Immunotherapy, vol. 58, no. 3, pp. 449–459, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Demaria, M. D. Volm, R. L. Shapiro et al., “Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy,” Clinical Cancer Research, vol. 7, no. 10, pp. 3025–3030, 2001. View at Google Scholar · View at Scopus
  34. M. Ono, H. Tsuda, C. Shimizu et al., “Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer,” Breast Cancer Research and Treatment, vol. 132, no. 3, pp. 793–805, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. N. R. West, K. Milne, P. T. Truong, N. Macpherson, B. H. Nelson, and P. H. Watson, “Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer,” Breast Cancer Research, vol. 13, no. 6, article R126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Loi, N. Sirtaine, F. Piette et al., “Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98,” Journal of Clinical Oncology, vol. 31, no. 7, pp. 860–867, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Droeser, I. Zlobec, E. Kilic et al., “Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers,” BMC Cancer, vol. 12, article 134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. S. D. Heys, K. N. Stewart, E. J. McKenzie et al., “Characterisation of tumour-infiltrating macrophages: Impact on response and survival in patients receiving primary chemotherapy for breast cancer,” Breast Cancer Research and Treatment, vol. 135, no. 2, pp. 539–548, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Matkowski, I. Gisterek, A. Halon et al., “The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer,” Anticancer Research, vol. 29, no. 7, pp. 2445–2451, 2009. View at Google Scholar · View at Scopus
  40. S. Ladoire, G. Mignot, S. Dabakuyo et al., “In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival,” The Journal of Pathology, vol. 224, no. 3, pp. 389–400, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. A. C. Degnim, R. D. Brahmbhatt, D. C. Radisky et al., “Immune cell quantitation in normal breast tissue lobules with and without lobulitis,” Breast Cancer Research and Treatment, vol. 144, no. 3, pp. 539–549, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. H. J. Lee, J.-Y. Seo, J.-H. Ahn, S.-H. Ahn, and G. Gong, “Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients,” Journal of Breast Cancer, vol. 16, no. 1, pp. 32–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. A. N. Seo, H. J. Lee, E. J. Kim et al., “Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer,” British Journal of Cancer, vol. 109, no. 10, pp. 2705–2713, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. E. García-Martínez, G. L. Gil, A. C. Benito et al., “Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer,” Breast Cancer Research, vol. 16, no. 6, article 488, 2014. View at Publisher · View at Google Scholar
  45. H. Sewell, “Basic immunology,” in Essential Immunology for Surgeons, O. Eremin and H. Sewell, Eds., chapter 1, pp. 1–160, OUP, Oxford, UK, 2011. View at Google Scholar
  46. C. T. Mayer, S. Floess, A. M. Baru, K. Lahl, J. Huehn, and T. Sparwasser, “CD8+Foxp3+ T cells share developmental and phenotypic features with classical CD4+Foxp3+ regulatory T cells but lack potent suppressive activity,” European Journal of Immunology, vol. 41, no. 3, pp. 716–725, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Liu, Y. Li, M. Ren et al., “Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients,” Breast Cancer Research and Treatment, vol. 135, no. 2, pp. 459–467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. G. J. Bates, S. B. Fox, C. Han et al., “Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse,” Journal of Clinical Oncology, vol. 24, no. 34, pp. 5373–5380, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. A. M. Wolf, D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, and B. Grubeck-Loebenstein, “Increase of regulatory T cells in the peripheral blood of cancer patients,” Clinical Cancer Research, vol. 9, no. 2, pp. 606–612, 2003. View at Google Scholar · View at Scopus
  50. S. A. Perez, M. V. Karamouzis, D. V. Skarlos et al., “CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients,” Clinical Cancer Research, vol. 13, no. 9, pp. 2714–2721, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. D. J. Campbell and M. A. Koch, “Phenotypical and functional specialization of FOXP3+ regulatory T cells,” Nature Reviews Immunology, vol. 11, no. 2, pp. 119–130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. E. M. Shevach, “Mechanisms of Foxp3+ T regulatory cell-mediated suppression,” Immunity, vol. 30, no. 5, pp. 636–645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Nishikawa and S. Sakaguchi, “Regulatory T cells in tumor immunity,” International Journal of Cancer, vol. 127, no. 4, pp. 759–767, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. U. K. Liyanage, T. T. Moore, H.-G. Joo et al., “Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma,” Journal of Immunology, vol. 169, no. 5, pp. 2756–2761, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. R. P. Petersen, M. J. Campa, J. Sperlazza et al., “Tumor infiltrating FOXP3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients,” Cancer, vol. 107, no. 12, pp. 2866–2872, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. Q. Gao, S.-J. Qiu, J. Fan et al., “Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection,” Journal of Clinical Oncology, vol. 25, no. 18, pp. 2586–2593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Ladoire, F. Martin, and F. Ghiringhelli, “Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer,” Cancer Immunology, Immunotherapy, vol. 60, no. 7, pp. 909–918, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Gobert, I. Treilleux, N. Bendriss-Vermare et al., “Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome,” Cancer Research, vol. 69, no. 5, pp. 2000–2009, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. N. R. West, S. E. Kost, S. D. Martin et al., “Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer,” British Journal of Cancer, vol. 108, no. 1, pp. 155–162, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Ladoire, L. Arnould, G. Mignot et al., “Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy,” Breast Cancer Research and Treatment, vol. 125, no. 1, pp. 65–72, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. W. A. Teft, M. G. Kirchhof, and J. Madrenas, “A molecular perspective of CTLA-4 function,” Annual Review of Immunology, vol. 24, pp. 65–97, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. W. A. Teft and J. Madrenas, “Molecular determinants of inverse agonist activity of biologicals targeting CTLA-4,” Journal of Immunology, vol. 179, no. 6, pp. 3631–3637, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. M. K. Levings, R. Sangregorio, and M.-G. Roncarolo, “Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function,” The Journal of Experimental Medicine, vol. 193, no. 11, pp. 1295–1302, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. D. M. Sansom and L. S. K. Walker, “The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology,” Immunological Reviews, vol. 212, pp. 131–148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. T. L. Walunas, C. Y. Bakker, and J. A. Bluestone, “CTLA-4 ligation blocks CD28-dependent T cell activation,” The Journal of Experimental Medicine, vol. 183, no. 6, pp. 2541–2550, 1996. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Mao, L. Zhang, Y. Yang et al., “New insights of CTLA-4 into its biological function in breast cancer,” Current Cancer Drug Targets, vol. 10, no. 7, pp. 728–736, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. L. de la Cruz-Merino, A. Barco-Sánchez, F. Henao Carrasco et al., “New insights into the role of the immune microenvironment in breast carcinoma,” Clinical & Developmental Immunology, vol. 2013, Article ID 785317, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Shinohara, M. Taniwaki, Y. Ishida, M. Kawaichi, and T. Honjo, “Structure and chromosomal localization of the human PD-1 gene (PDCD1),” Genomics, vol. 23, no. 3, pp. 704–706, 1994. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Y. Park, M. J. Jang, Y. H. Chung et al., “Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB,” International Immunopharmacology, vol. 9, no. 13-14, pp. 1530–1539, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. S. L. Topalian, C. G. Drake, and D. M. Pardoll, “Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity,” Current Opinion in Immunology, vol. 24, no. 2, pp. 207–212, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Ostrand-Rosenberg, L. A. Horn, and S. T. Haile, “The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity,” Journal of Immunology, vol. 193, no. 8, pp. 3835–3841, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. C. Criscitiello and G. Curigliano, “Immunotherapeutics for breast cancer,” Current Opinion in Oncology, vol. 25, no. 6, pp. 602–608, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Dong, S. E. Strome, D. R. Salomao et al., “Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion,” Nature Medicine, vol. 8, no. 8, pp. 793–800, 2002. View at Publisher · View at Google Scholar
  74. Y. Cao, L. Zhang, P. Ritprajak et al., “Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis,” Cancer Research, vol. 71, no. 14, pp. 4737–4741, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Flemming, “Cancer: PD1 makes waves in anticancer immunotherapy,” Nature Reviews Drug Discovery, vol. 11, no. 8, article 601, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Sun, X. Fei, Y. Mao et al., “PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients,” Cancer Immunology, Immunotherapy, vol. 63, no. 4, pp. 395–406, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Chouaib, C. Asselin-Paturel, F. Mami-Chouaib, A. Caignard, and J. Y. Blay, “The host-tumor immune conflict: from immunosuppression to resistance and destruction,” Immunology Today, vol. 18, no. 10, pp. 493–497, 1997. View at Publisher · View at Google Scholar · View at Scopus
  78. T. E. Reichert, S. Watkins, J. Stanson, J. T. Johnson, and T. L. Whiteside, “Endogenous IL-2 in cancer cells: a marker of cellular proliferation,” Journal of Histochemistry and Cytochemistry, vol. 46, no. 5, pp. 603–611, 1998. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Schweyer, A. Soruri, J. Peters, A. Wagner, H. J. Radzun, and A. Fayyazi, “Malignant germ cell tumours of the testis express interferon-γ, but are resistant to endogenous interferon-γ,” British Journal of Cancer, vol. 89, no. 5, pp. 915–921, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Llanes-Fernández, R. I. Álvarez-Goyanes, M. D. C. Arango-Prado et al., “Relationship between IL-10 and tumor markers in breast cancer patients,” Breast, vol. 15, no. 4, pp. 482–489, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Yang, Y. Qi, J. Hu, L. Tang, S. Zhao, and B. Shan, “Expression of Th17 cells in breast cancer tissue and its association with clinical parameters,” Cell Biochemistry and Biophysics, vol. 62, no. 1, pp. 153–159, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. Q. Liu, M. R. Russell, K. Shahriari et al., “Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features,” Cancer Research, vol. 73, no. 11, pp. 3297–3305, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. F. Nutter, I. Holen, H. K. Brown et al., “Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line,” Endocrine-Related Cancer, vol. 21, no. 2, pp. 327–341, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. R. A. Flavell, S. Sanjabi, S. H. Wrzesinski, and P. Licona-Limón, “The polarization of immune cells in the tumour environment by TGFβ,” Nature Reviews Immunology, vol. 10, no. 8, pp. 554–567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. P. Maerten, C. Shen, D. M. A. Bullens et al., “Effects of interleukin 4 on CD25+CD4+ regulatory T cell function,” Journal of Autoimmunity, vol. 25, no. 2, pp. 112–120, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. B. B. L. Pillemer, Z. Qi, B. Melgert, T. B. Oriss, P. Ray, and A. Ray, “STAT6 activation confers upon T helper cells resistance to suppression by regulatory T cells,” Journal of Immunology, vol. 183, no. 1, pp. 155–163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. T. Kato, H. Furumoto, T. Ogura et al., “Expression of IL-17 mRNA in ovarian cancer,” Biochemical and Biophysical Research Communications, vol. 282, no. 3, pp. 735–738, 2001. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Numasaki, J.-I. Fukushi, M. Ono et al., “Interleukin-17 promotes angiogenesis and tumor growth,” Blood, vol. 101, no. 7, pp. 2620–2627, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. T. Yamazaki, X. O. Yang, Y. Chung et al., “CCR6 regulates the migration of inflammatory and regulatory T cells,” Journal of Immunology, vol. 181, no. 12, pp. 8391–8401, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. F. Benchetrit, A. Ciree, V. Vives et al., “Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism,” Blood, vol. 99, no. 6, pp. 2114–2121, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. C. M. Wilke, I. Kryczek, S. Wei et al., “Th17 cells in cancer: help or hindrance?” Carcinogenesis, vol. 32, no. 5, pp. 643–649, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. B. Bierie and H. L. Moses, “Transforming growth factor beta (TGF-β) and inflammation in cancer,” Cytokine & Growth Factor Reviews, vol. 21, no. 1, pp. 49–59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. G. Wei, L. Wei, J. Zhu et al., “Global mapping of H3K4me3 and H3k27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells,” Immunity, vol. 30, no. 1, pp. 155–167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. L. Xu, A. Kitani, I. Fuss, and W. Strober, “Cutting edge: regulatory T cells induce CD4+CD25Foxp3 T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-β,” The Journal of Immunology, vol. 178, no. 11, pp. 6725–6729, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. N. Tsavaris, C. Kosmas, M. Vadiaka, P. Kanelopoulos, and D. Boulamatsis, “Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes,” British Journal of Cancer, vol. 87, no. 1, pp. 21–27, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. C. M. Barbon, M. Yang, G. D. Wands et al., “Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization,” Cellular Immunology, vol. 262, no. 2, pp. 150–161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. D. T. Le and E. M. Jaffee, “Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective,” Cancer Research, vol. 72, no. 14, pp. 3439–3444, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. N. Casares, M. O. Pequignot, A. Tesniere et al., “Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death,” The Journal of Experimental Medicine, vol. 202, no. 12, pp. 1691–1701, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. A. D. Garg, D. V. Krysko, T. Verfaillie et al., “A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death,” The EMBO Journal, vol. 31, no. 5, pp. 1062–1079, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. L. Menger, E. Vacchelli, S. Adjemian et al., “Cardiac glycosides exert anticancer effects by inducing immunogenic cell death,” Science Translational Medicine, vol. 4, no. 143, Article ID 143ra99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. S. R. Mattarollo, S. Loi, H. Duret, Y. Ma, L. Zitvogel, and M. J. Smyth, “Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors,” Cancer Research, vol. 71, no. 14, pp. 4809–4820, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. F. Ghiringhelli, C. Menard, P. E. Puig et al., “Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients,” Cancer Immunology, Immunotherapy, vol. 56, no. 5, pp. 641–648, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. A. W. Tong, B. Seamour, J. M. Lawson et al., “Cellular immune profile of patients with advanced cancer before and after taxane treatment,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 23, no. 5, pp. 463–472, 2000. View at Publisher · View at Google Scholar · View at Scopus
  104. G. M. Weir, R. S. Liwski, and M. Mansour, “Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines,” Cancers, vol. 3, no. 3, pp. 3114–3142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Vincent, G. Mignot, F. Chalmin et al., “5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity,” Cancer Research, vol. 70, no. 8, pp. 3052–3061, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. E. J. Wherry and M. Kurachi, “Molecular and cellular insights into T cell exhaustion,” Nature Reviews Immunology, vol. 15, no. 8, pp. 486–499, 2015. View at Publisher · View at Google Scholar · View at Scopus